The 10th annual Amsterdam Immunogenicity and Tolerance Seminar was a fantastic success, bringing together a passionate group of immunology and vaccinology experts to explore new frontiers in the field.
The morning sessions focused on protein therapeutics, with engaging discussions on how tolerance can impact immunogenicity risk assessment and enhance therapeutic applications.
In the afternoon, we shifted our attention to vaccine efficacy and its unexpected effects, featuring remarkable insights from our keynote speaker, Peter Aaby, whose work has inspired fresh perspectives on evaluating vaccines beyond antibody titers. Mihai Netea’s contributions on trained innate immunity added depth to this conversation, and we were thrilled to hear from Femke Broere on promising results in tolerance induction for rheumatoid arthritis.
The audience’s energy and curiosity were incredible, and their thoughtful questions kept the dialogue going strong. Thank you to everyone who attended and contributed to this vibrant exchange—we can’t wait to gather again next year!
Join us in Amsterdam!
The 10th annual Amsterdam Immunogenicity and Tolerance Seminar will take place on Friday, November 8th, 2024 from 9:30am – 7:30 pm. All events (including a networking session with beer, wine and snacks!) will be located at the Hilton Apollolaan in Amsterdam.
About the Amsterdam Immunogenicity & Tolerance Seminar:
Now in its 10th year, The Amsterdam Immunogenicity & Tolerance Seminar will showcase talks from expert biologics and vaccine developers from industry and academia highlighting how immunogenicity and tolerance have played a role in their recent work.
Speakers for this year include visionaries from Leiden University Medical Centre, Pfizer, Inc., Utrecht University, EpiVax, Inc., and more. Topics will cover updates on the preclinical and clinical development of tolerance-inducing therapies for autoimmune diseases, immunogenicity assessment strategies and case studies for selection of optimal biologics and vaccines, and updates on how to address hyporesponsiveness and off-target effects of vaccines.
In addition to the talks, there will be networking opportunities, poster presentations, and more.
As a leader in the field of preclinical immunogenicity assessment, design, and optimization of biologics and vaccines, in addition to a developer of a tolerance-inducing therapy, EpiVax hosts this seminar to connect with Europe-based collaborators and to bring industry and academic experts together to share new ideas and present research updates in the space.
Please note: This is an in-person event with no options for virtual attendance.
Check out past year’s AIT Seminars:
2023 Amsterdam Immunogenicity & Tolerance Seminar
2021 Amsterdam Immunogenicity & Tolerance Seminar
Click to expand and download. Subject to change.
A special thanks to the AIT23 Organizing Committee:
Corine Kruiswijk Director, Translational Research, Intravacc
Marcel Hoefnagel Senior Scientist/Assessor, College ter Beoordeling van Geneesmiddelen
Elly van Riet Senior Scientist, TuBerculosis Vaccine Initiative
Annie De Groot CEO/CSO, EpiVax Inc.
Femke Broere Professor of Translational Immunology, Faculty of Veterinary Medicine, Utrecht University
Brian Roberts Scientific Director, Preclinical Immunology, EpiVax Inc.
Questions or suggestions? Contact EpiVax: [email protected]
